Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of Ooma, Inc. (NYSE:OOMA) rose sharply in today’s pre-market trading after the company reported better-than-expected first-quarter financial…
Syndax Presents Data From Pivotal AUGMENT-101 Trial Of Revumenib In Relapsed/Refractory KMT2Ar Acute Leukemia At Oral Presentation During ASH Meeting; Trial Met Its Primary Endpoint At Interim Analysis Of The Pooled KMT2Ar AML And ALL Cohorts
– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients –– 63% overall response
What’s Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today?
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2r) relapsed/refractory
Incyte And Syndax Present Additional Data From Positive AGAVE-201 Trial At ASH Plenary Session Showing Axatilimab Efficacy
- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment
- Data are
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers TRACON Pharma (NASDAQ:TCON) stock increased by 71.3% to $0.27 during Thursday’s after-market session. This security traded at…
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell
• AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Earnings Outlook For Syndax Pharmaceuticals
Syndax Pharmaceuticals (NASDAQ:SNDX) is set to give its latest quarterly earnings report on Thursday, 2023-11-02. Here’s what investors…
Benzinga’s Top Ratings Upgrades, Downgrades For October 11, 2023
Upgrades For Coherent Corp (NYSE:COHR), B. Riley Securities upgraded the previous rating of Neutral to Buy. In the…
